No material corporate news briefings were recorded for Amgen Inc. in the 30 days preceding this report's generation date of 2026-08-12. Consecutive prior reports dated 2026-08-04, 2026-07-27, and 2026-07-19 similarly noted the absence of material corporate news events within their respective windows [Brief - 2026-08-04].
Amgen's trailing twelve-month revenue stood at $38.10 billion as of 2026-06-30, reflecting year-over-year growth of 9.53%. Net income over the same period totalled $8.74 billion, with a net margin of 22.95% and an operating margin of 29.99%. Gross margin was recorded at 47.46%. EPS grew 64.91% year-over-year. The company held $13.99 billion in cash against total debt of $59.30 billion. Market capitalisation was approximately $223.97 billion, and the trailing P/E ratio was 25.75 [SEC 10-Q - AMGN - 2026-06-30].
Insider activity in August 2026 comprised 11 transactions with a net direction of selling, totalling a net disposal value of approximately $2.76 million [SEC Form 4 - AMGN - 2026-08]. No notable institutional 13F filing changes were available in the provided context for this reporting period.
The prevailing macro environment features a 10-year US Treasury yield of 4.72% and a 2-year yield of 4.25%, representing a normal yield curve with a spread of 47 basis points [FRED DGS10] [FRED DGS2]. This report was generated in response to a new SEC filing and recent insider activity recorded for Amgen Inc.